News

Supernus bolsters Parkinson’s portfolio with $400 million deal for Adamas Pharma

(October 11, 2021) – Supernus Pharmaceuticals Inc (SUPN.O) said on Monday it would buy Adamas Pharmaceuticals Inc (ADMS.O) for roughly $400 million. The purchase expands Supernus’ roster of treatments for Parkinson’s disease and reduces reliance on its top-selling epilepsy medicine. Supernus will gain access to Adamas’ products Gocovri extended release capsules and Osmolex ER for treating Parkinson’s disease. Click here to learn more about Supernus’ purchase of Adamas.

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2020 The Parkinson Alliance. All rights reserved.